NWBO · Northwest Biotherapeutics Inc
$0.17
0.00 (-0.99%)
At close · Aug 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, however, they do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Market Cap
$289.96M
Shares
1.71B
Volume · Aug 21
3.19M
Avg daily vol (3M)
2.98M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.17
Open$0.17
Day$0.16–0.18
52W close$0.15–0.32
Avg vol 30d3.0M
Short int69.9M · 4.1% float · 10.8d
Short vol30%
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.17M
Trailing 12 months
Net income (TTM)
−$37.73M
Trailing 12 months
Revenue growth YoY
+516.0%
Year over year
Operating margin
-2,316.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-17.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$51.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.2%
Year over year · more shares
Price change (1Y)
-32.2%
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−5%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
12%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−26%
trailing
YTD return
−26%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.10% of float · ▼ -0.2% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Fundamentals
Revenue growth
+15%
Y/Y
EPS growth
+43%
Y/Y
Free cash flow
$-46.3M
Balance sheet
$57.0M
net debt
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−5%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.10% of float · ▼ -0.2% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 12%
Range high $0
vs 200-day avg -23%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NWBO
this stock
Northwest Biotherapeutics Inc
|
$289.96M | -26.3% | +14.8% | — | 4.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
8
- % held
- 0.1%
- Net QoQ
- +1.8M sh
- Top holder
- COMPASS FINANCIAL MANAGEM…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NWBO | -11.7% | -0.2% | -26.3% | +6.0% | -26.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -10.3% | -3.9% | -37.8% | +3.5% | -38.6% |